Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

104.87 +1.06 (+1.02%)
Official Closing Price Updated: 7:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis Ag ADR

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
42 43 Next >
Novartis' Ligelizumab Suffers Setback In Late-Stage Skin Disorder Studies
Novartis AG (NYSE: NVS) said that its ligelizumab antibody treatment against recurring hives did not meet the goal of superiority to standard treatment Xolair (... 
Via Benzinga
The Week In Cannabis: Pfizer, Visa, $730M+ In Financings, Malta, EU, Columbia Care, MedMen, Uruguay And More
Below is a recap of the main news related to the cannabis industry and markets for the week of December 13, 2021. 
Via Benzinga
The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug... 
Via Benzinga
Oncology Drugs Market Comprehensive Study Explore Huge Growth in Future
Stay up-to-date with Oncology Drugs Market research offered by HTF MI. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
Exposures COVID-19
Novartis Launches New Share Buyback Program Of Up To $15B
Novartis AG (NYSE: NVS) is launching a new share buyback worth up to $15 billion to be executed by the end of 2023, adding it was confident in its top-line growth... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're at the halfway point of the week but there's no slowing down as we dive into the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
Molecular Partners Inks License Deal With Novartis For $580M
Molecular Partners AG (NASDAQ: MOLN) entered into a license agreement with Novartis AG (NYSE: NVS) to develop, manufacture, and commercialize DARPin-... 
Via Benzinga
The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Vaccitech To Buy Avidea For $40M Vaccitech plc (NASDAQ: VACC) announced that... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, trader! It's time to start off the day with a breakdown of the biggest pre-market stock movers for Tuesday! 
Via InvestorPlace
Theramex Names Camilla Harder Hartvig As New Chief Commercial Officer
Via Get News
How Pfizer Is Getting Into Cannabis With $6.7B Arena Pharma Deal
The two publicly-traded companies confirmed Monday that they have signed a definitive agreement under which Pfizer will acquire all outstanding shares of Arena for $100 per share in an all-cash... 
Via Talk Markets
Topics Cannabis
Exposures Cannabis
How Pfizer Is Getting Into Cannabis With $6.7B Arena Pharma Deal
Pharmaceutical giant Pfizer Inc. (NYSE:PFE) is e... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
7 CEOs That Ought to Follow Jack Dorsey Out the Door
Jack Dorsey stepped down as Twitter CEO despite stock gains, but not every CEO can say the same. Here are seven CEOs who need to go. 
Via InvestorPlace
Omicron Surge
The seemingly good level of joblessness at a mere 184,000 turns out to be less wonderful than it appears, at the lowest since 1969. 
Via Talk Markets
Novartis Reveals Two Year Results From Beovu Trial In Diabetic Macular Edema Patients
Novartis AG (NYSE: NVS) has reported the first interpretable results from year two (week 100) of the Phase 3 KESTREL study of Beovu (brolucizumab) 6 mg in patients... 
Via Benzinga
Novartis' New Kisqali Data Shows Consistent Overall Survival Benefit Across Metastatic Breast Cancer Settings
Novartis AG (NYSE: NVS) shared new data from the MONALEESA Phase 3 program of Kisqali (ribociclib), the CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer and... 
Via Benzinga
Super Generic Drugs Market to See Major Growth by 2027 : Lupin, Apotex, Sanofi, Aurobindo, Dr.Reddy's
Get an extensive Super Generic Drugs Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry. 
Via SBWire
Topics Supply Chain
Exposures Supply Chain
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2021
Upgrades According to TD Securities, the prior rating for MAG Silver Corp (AMEX: 
Via Benzinga
Thursday Markets Overview
Today we are seeing an across-the-board rise in stock prices on hopes for lower inflation and Omicron jabbing. 
Via Talk Markets
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
Exposures Product Safety
Aurinia Pharma Surges Again As Novartis Joins List Of Potential Suitors
Aurinia Pharma popped after Novartis said it's focused on bolt-on deals. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For December 3, 2021
Upgrades Cowen & Co. upgraded the previous rating for Marvell Technology Inc (NASDAQ: 
Via Benzinga
Gene Therapy-Focused Dyno Therapeutics Adds Astellas To List Partner List With $1.6B Pact
Gene therapy startup Dyno Therapeutics Inc has partnered with pharmaceutical giants such as Novartis AG (NYSE: NVS) and Roche Holdings AG (OTC: RHHBY... 
Via Benzinga
AI for Pharma and Biotech Market Next Big Thing : Major Giants Atomwise, CloudMedX, Roche
Stay up-to-date with AI for Pharma and Biotech Market research offered by HTF MI. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
AUPH Stock: The Novartis Takeover Talk That Has Aurinia Pharma Shares Taking Off Today
Aurinia Pharma (AUPH) stock is on the rise Thursday as investors hold out hope for a takeover of the company by Novartis (NVS). 
Via InvestorPlace
Breakthrough Cancer Therapy? This Biotech Shares Preclinical Data and Ambitious Plans
Photo by National Cancer Institute on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a... 
Via Benzinga
The Daily Biotech Pulse: Moderna, Pfizer-BioNTech Ink New Vaccine Deals With UK, GSK-Vir Antibody Show Activity Against Omicron, Chemomab Gets Clearance
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus U.K. Signs Deal to Buy Incremental COVID-19 Vaccines From Moderna And Pfizer-... 
Via Benzinga
Exposures COVID-19
Mr. Market Will Shop ‘til He Drops!
Via Talk Markets
How one mother is raising awareness for spinal muscular atrophy – a leading genetic cause of infant death
(BPT) - When Nicole Clark's son Brady was born, he was reaching his normal early milestones: holding his head up on his own, sitting and crawling. But when Nicole's energetic and seemingly healthy... 
Via Brandpoint
Exposures Product Safety
Pediatric Drugs and Vaccines Market SWOT Analysis by Roche, Abbott Laboratories, Amgen
Stay up-to-date with Pediatric Drugs and Vaccines Market research offered by HTF MI. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
Exposures COVID-19
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
42 43 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.